CA2654113A1 - Formulations a liberation prolongee d'inhibiteurs de l'aromatase - Google Patents

Formulations a liberation prolongee d'inhibiteurs de l'aromatase Download PDF

Info

Publication number
CA2654113A1
CA2654113A1 CA002654113A CA2654113A CA2654113A1 CA 2654113 A1 CA2654113 A1 CA 2654113A1 CA 002654113 A CA002654113 A CA 002654113A CA 2654113 A CA2654113 A CA 2654113A CA 2654113 A1 CA2654113 A1 CA 2654113A1
Authority
CA
Canada
Prior art keywords
microparticles
sustained release
letrozole
release formulation
polymeric matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002654113A
Other languages
English (en)
Inventor
Oliver Lambert
Marc Riemenschnitter
Vitomir Vucenovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2654113A1 publication Critical patent/CA2654113A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002654113A 2006-06-22 2007-06-20 Formulations a liberation prolongee d'inhibiteurs de l'aromatase Abandoned CA2654113A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80550806P 2006-06-22 2006-06-22
US60/805,508 2006-06-22
PCT/EP2007/056166 WO2007147861A2 (fr) 2006-06-22 2007-06-20 Formulations à libération prolongée d'inhibiteurs de l'aromatase

Publications (1)

Publication Number Publication Date
CA2654113A1 true CA2654113A1 (fr) 2007-12-27

Family

ID=38704831

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002654113A Abandoned CA2654113A1 (fr) 2006-06-22 2007-06-20 Formulations a liberation prolongee d'inhibiteurs de l'aromatase

Country Status (9)

Country Link
EP (1) EP2037884A2 (fr)
JP (1) JP2009541264A (fr)
KR (1) KR20090026345A (fr)
CN (1) CN101511341A (fr)
AU (1) AU2007263004A1 (fr)
CA (1) CA2654113A1 (fr)
MX (1) MX2008015917A (fr)
RU (1) RU2009101810A (fr)
WO (1) WO2007147861A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914767D0 (en) * 2009-08-24 2009-09-30 Sterix Ltd Compound
WO2012082165A1 (fr) * 2010-01-24 2012-06-21 Novartis Ag Microparticules de polymère biodégradable irradiées
WO2013063125A1 (fr) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Compositions implantable pour administration de médicaments et méthodes de traitement correspondantes
WO2016020901A1 (fr) 2014-08-07 2016-02-11 Acerta Pharma B.V. Procédés de traitement de cancers, maladies immunitaires et auto-immunes, et maladies inflammatoires basés sur l'occupation de btk et le taux de resynthèse de btk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670516A2 (fr) * 2003-09-30 2006-06-21 Solubest Ltd Nanoparticules hydrosolubles et leur procede de production
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation

Also Published As

Publication number Publication date
JP2009541264A (ja) 2009-11-26
CN101511341A (zh) 2009-08-19
RU2009101810A (ru) 2010-07-27
EP2037884A2 (fr) 2009-03-25
AU2007263004A1 (en) 2007-12-27
WO2007147861A2 (fr) 2007-12-27
MX2008015917A (es) 2009-01-13
WO2007147861A3 (fr) 2008-02-07
KR20090026345A (ko) 2009-03-12

Similar Documents

Publication Publication Date Title
TWI469788B (zh) 包含奧曲肽（ｏｃｔｒｅｏｔｉｄｅ）及二或多個聚乳酸交酯-乙交酯共聚物之持續釋放調配物
US20240082148A1 (en) Octreotide Depot Formulation with Constantly High Exposure Levels
EP1686964B1 (fr) Composition pharmaceutique
US9351923B2 (en) Extended-release composition comprising a somatostatin derivative in microparticles
JP2015107985A (ja) オクトレオチドおよび３種の線状ポリラクチド−コ−グリコリドポリマーを含む徐放性製剤
CA2654113A1 (fr) Formulations a liberation prolongee d'inhibiteurs de l'aromatase
AU2013201877B2 (en) Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers

Legal Events

Date Code Title Description
FZDE Discontinued